Advertisement

Picture Berlin Partner Life Sciences Report 2019/2020 Brandenburg 650x80px
Document › Details

ERS Genomics Ltd.. (2/16/21). "Press Release: ERS Genomics and ZeClinics Sign CRISPR/Cas9 License Agreement". Dublin & Barcelona.

Organisations Organisation ERS Genomics Ltd.
  Organisation 2 ZeClinics (ES)
Products Product CRISPR-Cas9 technology
  Product 2 zebrafish screening technology
Persons Person Rhodes, Eric (ERS Genomics 201606– CEO before Horizon Discovery since 201201 before Sigma-Aldrich + Sangamo Biosciences)
  Person 2 Calzolari, Simone (ZeClinics 202102 CEO + Co-Founder)
     


ZeClinics is applying CRISPR technology to create gene edited zebrafish disease models


ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and ZeClinics, a contract research organization using zebrafish to carry out services focused on analyzing the safety, efficacy and biomedical relevance of new compounds, today announced a non-exclusive license agreement granting ZeClinics access to ERS Genomics’ CRISPR/Cas9 patent portfolio.

ZeClinics supports academic, pharmaceutical and biotech organizations in pre-clinical studies by providing services based on its zebrafish disease models. The Company is applying CRISPR/Cas9 technology to create single knock-out, double knock-out and somatic F0 knock-out zebrafish variants.

“CRISPR/Cas9 has become an important tool in many areas of research. At ERS we are expanding our efforts to make the technology broadly available, so it can be used by as many people as possible, and we are therefore pleased to support ZeClinics with this license agreement,” said Eric Rhodes, CEO of ERS Genomics. “By providing them access to this foundational CRISPR/Cas9 intellectual property, ZeClinics is able to continue to provide valuable preclinical models and services for drug discovery and development.”

“The zebrafish model is a powerful tool for answering complex questions,” commented Simone Calzolari, CEO and Co-founder, ZeClinics. “The use of CRISPR tools to modify zebrafish models allows us to streamline functional genomic processes, provide insights into biologically relevant knowledge on diseases. The license from ERS expands our CRISPR IP portfolio and, alongside the license from The Broad Institute, allows us to push ahead with the application of this advanced technology, ultimately increasing the validity and potency of zebrafish models for the drug discovery process.”

Financial details of the agreement are not disclosed.


ENDS


Media contact:

Katie Odgaard
Zyme Communications
Tel: +44(0)7787 502 947
Email: katie.odgaard@zymecommunications.com

Contact ZeClinics:

Sandra Ciller
Marketing Manager, ZeClinics
Email: sandra.ciller@zeclinics.com


About ERS Genomics www.ersgenomics.com

ERS Genomics is a biotechnology company based in Dublin, Ireland. The company was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property held by Dr. Emmanuelle Charpentier. Non-exclusive licenses are available for research and sale of products and services across multiple fields including: research tools, kits, reagents; discovery of novel targets for therapeutic intervention; cell lines for discovery and screening of novel drug candidates; GMP production of healthcare products; companion animal and livestock health; production of industrial materials such as enzymes, biofuels and chemicals; and synthetic biology. For additional information please visit www.ersgenomics.com.


About ZeClinics www.zeclinics.com

ZeClinics is an innovative biotech firm committed to streamlining discovery and preclinical development of novel compounds with zebrafish, an ideal vertebrate model for fast, cost-effective, and highly predictive assessments. ZeClinics combines in-house academic expertise with a diversified, cutting-edge portfolio: from CRISPR-licensed gene editing, high-throughput safety and efficacy assays to disease models.

For more information, please visit www.zeclinics.com

   
Record changed: 2021-03-01

Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for ERS Genomics Ltd.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [iito] Back into Ad 650x80px




» top